CNS5:Diffuse astrocytoma, MYB- or MYBL1-altered
Primary Author(s)*
Scott C. Smith, PhD, FACMG; SUNY Upstate Medical University
Cancer Category/Type
WHO Classification of Tumours of the Central Nervous System (5th Edition)
Cancer Sub-Classification / Subtype
Diffuse Astrocytoma, MYB- or MYBL1-Altered
Definition / Description of Disease
Diffuse astrocytoma, MYB or MYBL1-altered is one of several newly recognized tumor types in the 5th edition of the WHO Classification of Tumors of the Central Nervous System. The newly recognized classifications were in response to advances in understanding of paediatric-type gliomas, facilitated by an increased molecular characterisation of these tumours. Diffuse astrocytoma, MYB or MYBL1-altered is a subset of diffuse low-grade glioma with amplifications, structural variants, and fusions involving the MYB and MYBL1 protooncogenes. Diffuse astrocytoma, MYB or MYBL1-altered subtypes are without characteristic histological features of angiocentric glioma[1][2]. A related group of diffuse gliomas, the isomorphic glioma, occur predominantly in adults and are typically well-differentiated, low to moderately cellular, comprised of astrocytes with rounded nuclei and regular chromatin structures, and have low proliferative indices[3][4]. These adult diffuse gliomas exhibit alterations of MYBL1 rather than MYB . Gene fusions with multiple partners characterize the pediatric MYB or MYBL1-altered gliomas[5][6]. The most frequently identified fusion is with QKI[7][8]. The MYB or MYBL1-altered diffuse gliomas in both children and adults are generally indolent and behave in a WHO grade 1 fashion.
Clinical Features
Medically refractory epilepsy since childhood.
Signs and Symptoms | History of epilepsy or seizure
Magnetic resonance imaging (MRI): well-delineated, occasionally infiltrative-appearing, non-enhancing T1-hypointense, T2-fluid attenuated inversion recovery-hyperintense lesion without restricted diffusion[9] |
Laboratory Findings | Genetics: Negative for IDH1 p.R132H, BRAF p.V600E; positive for MYBL1 or MYB rearrangement, amplification, or copy number change |
Sites of Involvement
Supratentorial (adult), cortical and subcortical regions of the cerebral cortex (pediatric)[10]
Morphologic Features
Histomorphology: minimally to moderately hypercellular tumor; diffuse infiltration by monomorphic cells with ovoid to elongated nuclei, scant cytoplasm, fibrillary background[11][12]
Immunophenotype
Positivity for GFAP, below 1% Ki-67 index, negative for OLIG2 and IDH1 R132H[13]
Finding | Marker |
---|---|
Positive (universal) | GFAPScott C. Smith,
PhD, FACMG; SUNY Upstate Medical University |
Positive (subset) | Ki-67 index below 1% |
Negative (universal) | OLIG2, IDH1 R132H |
Chromosomal Rearrangements (Gene Fusions)
MYB or MYBL1 rearrangement
MYB or MYBL1 amplification
Chromosomal Rearrangement | Genes in Fusion (5’ or 3’ Segments) | Pathogenic Derivative | Prevalence | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
---|---|---|---|---|---|---|---|
6q23.3 rearrangement | Yes | Yes | Multiple potential partners | ||||
8q13.1 rearrangement | Yes | Yes | Multiple potential partners | ||||
del(6)(q23.3q26); t(6;6)(q23.3;q26) | MYB::QKI | Yes | Yes | Creates fusion oncogenic protein |
Individual Region Genomic Gain/Loss/LOH
MYB or MYBL1 copy number variation as identified by chromosomal microarray or FISH
Chr # | Gain / Loss / Amp / LOH | Minimal Region Genomic Coordinates [Genome Build] | Minimal Region Cytoband | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
---|---|---|---|---|---|---|---|
6 | Amp/Loss/Gain | 135502446-135540310 [GRCh37] | 6q23.3 | Yes | Yes | Yes[14] | [15][16][17] |
8 | Amp/Loss/Gain | 67474410-67525453 [GRCh37] | 8q13.1 | Yes | Yes | Unknown | [18][19] |
Characteristic Chromosomal Patterns
Possible detection of double minutes or homogeneously stained regions by G-banding for amplification; will require confirmation of being associated with MYB or MYBL (likely by chromosomal microarray)
Chromosomal Pattern | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
---|---|---|---|---|
6q23.3 hsr; MYB amplification Scott C. Smith,
PhD, FACMG; SUNY Upstate Medical University |
No | Unknown | Unknown | |
8q13.1 hsr; MYBL1 amplificationScott C. Smith,
PhD, FACMG; SUNY Upstate Medical University |
No | Unknown | Unknown |
Genes and Main Pathways Involved
Gene; Genetic Alteration | Pathway | Pathophysiologic Outcome |
---|---|---|
MYB/MYBL1 3’-deletion | MYB/MYBL1 protooncogene | Deregulation of MYB/MYBL1 |
MYB/MYBL1 amplification | MYB/MYBL1 protooncogene | Overexpression of MYB/MYBL1 |
Genetic Diagnostic Testing Methods
Sequencing, PCR, RT-PCR, chromosomal microarray, FISH, possibly detection of double minutes or homogenously stained regions by G-banding
References
- ↑ Slegers, Rutger Juriaan; et al. (2020-03-09). "Low-grade developmental and epilepsy associated brain tumors: a critical update 2020". Acta Neuropathologica Communications. 8 (1): 27. doi:10.1186/s40478-020-00904-x. ISSN 2051-5960. PMC 7063704 Check
|pmc=
value (help). PMID 32151273 Check|pmid=
value (help). - ↑ Bandopadhayay, Pratiti; et al. (2016-03). "MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism". Nature Genetics. 48 (3): 273–282. doi:10.1038/ng.3500. ISSN 1546-1718. PMC 4767685. PMID 26829751. Check date values in:
|date=
(help) - ↑ Wefers, Annika K.; et al. (2020-01). "Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course". Acta Neuropathologica. 139 (1): 193–209. doi:10.1007/s00401-019-02078-w. ISSN 1432-0533. PMC 7477753 Check
|pmc=
value (help). PMID 31563982. Check date values in:|date=
(help) - ↑ Chiang, Jason; et al. (2019-12). "A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration". Acta Neuropathologica. 138 (6): 1091–1092. doi:10.1007/s00401-019-02081-1. ISSN 1432-0533. PMC 7467132 Check
|pmc=
value (help). PMID 31595312. Check date values in:|date=
(help) - ↑ Ramkissoon, Lori A.; et al. (2013-05-14). "Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1". Proceedings of the National Academy of Sciences of the United States of America. 110 (20): 8188–8193. doi:10.1073/pnas.1300252110. ISSN 1091-6490. PMC 3657784. PMID 23633565.
- ↑ Barinfeld, Orit; et al. (2022). "Genetic Alteration Analysis of IDH1, IDH2, CDKN2A, MYB and MYBL1 in Pediatric Low-Grade Gliomas". Frontiers in Surgery. 9: 880048. doi:10.3389/fsurg.2022.880048. ISSN 2296-875X. PMC 9096721 Check
|pmc=
value (help). PMID 35574540 Check|pmid=
value (help). - ↑ Suh, Ye Yoon; et al. (2023-02-21). "MYB/MYBL1::QKI fusion-positive diffuse glioma". Journal of Neuropathology and Experimental Neurology. 82 (3): 250–260. doi:10.1093/jnen/nlac123. ISSN 1554-6578. PMC 9941827 Check
|pmc=
value (help). PMID 36592415 Check|pmid=
value (help). - ↑ Jain, Payal; et al. (2017-03-04). "MYB-QKI drives childhood brain tumors via tripartite mechanism". Cell Cycle (Georgetown, Tex.). 16 (5): 390–391. doi:10.1080/15384101.2016.1260990. ISSN 1551-4005. PMC 5351923. PMID 27973981.
- ↑ Fabbri, Viscardo Paolo; et al. (2022-12). "Paediatric-type diffuse low-grade gliomas: a clinically and biologically distinct group of tumours with a favourable outcome". Pathologica. 114 (6): 410–421. doi:10.32074/1591-951X-828. ISSN 1591-951X. PMC 9763978 Check
|pmc=
value (help). PMID 36534420 Check|pmid=
value (help). Check date values in:|date=
(help) - ↑ Fabbri, Viscardo Paolo; et al. (2022-12). "Paediatric-type diffuse low-grade gliomas: a clinically and biologically distinct group of tumours with a favourable outcome". Pathologica. 114 (6): 410–421. doi:10.32074/1591-951X-828. ISSN 1591-951X. PMC 9763978 Check
|pmc=
value (help). PMID 36534420 Check|pmid=
value (help). Check date values in:|date=
(help) - ↑ Fabbri, Viscardo Paolo; et al. (2022-12). "Paediatric-type diffuse low-grade gliomas: a clinically and biologically distinct group of tumours with a favourable outcome". Pathologica. 114 (6): 410–421. doi:10.32074/1591-951X-828. ISSN 1591-951X. PMC 9763978 Check
|pmc=
value (help). PMID 36534420 Check|pmid=
value (help). Check date values in:|date=
(help) - ↑ Suh, Ye Yoon; et al. (2023-02-21). "MYB/MYBL1::QKI fusion-positive diffuse glioma". Journal of Neuropathology and Experimental Neurology. 82 (3): 250–260. doi:10.1093/jnen/nlac123. ISSN 1554-6578. PMC 9941827 Check
|pmc=
value (help). PMID 36592415 Check|pmid=
value (help). - ↑ Wefers, Annika K.; et al. (2020-01). "Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course". Acta Neuropathologica. 139 (1): 193–209. doi:10.1007/s00401-019-02078-w. ISSN 1432-0533. PMC 7477753 Check
|pmc=
value (help). PMID 31563982. Check date values in:|date=
(help) - ↑ Trkova, Katerina; et al. (2023-09). "DIPG-like MYB-altered diffuse astrocytoma with durable response to intensive chemotherapy". Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery. 39 (9): 2509–2513. doi:10.1007/s00381-023-05976-3. ISSN 1433-0350. PMC PMC10432314 Check
|pmc=
value (help). PMID 37165121 Check|pmid=
value (help). Check date values in:|date=
(help)CS1 maint: PMC format (link) - ↑ Ramkissoon, Lori A.; et al. (2013-05-14). "Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1". Proceedings of the National Academy of Sciences of the United States of America. 110 (20): 8188–8193. doi:10.1073/pnas.1300252110. ISSN 1091-6490. PMC 3657784. PMID 23633565.
- ↑ Bale, Tejus A.; et al. (2022-07). "The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low-grade gliomas and glioneuronal tumors". Brain Pathology (Zurich, Switzerland). 32 (4): e13060. doi:10.1111/bpa.13060. ISSN 1750-3639. PMC 9245930 Check
|pmc=
value (help). PMID 35218102 Check|pmid=
value (help). Check date values in:|date=
(help) - ↑ Trkova, Katerina; et al. (2023-09). "DIPG-like MYB-altered diffuse astrocytoma with durable response to intensive chemotherapy". Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery. 39 (9): 2509–2513. doi:10.1007/s00381-023-05976-3. ISSN 1433-0350. PMC PMC10432314 Check
|pmc=
value (help). PMID 37165121 Check|pmid=
value (help). Check date values in:|date=
(help)CS1 maint: PMC format (link) - ↑ Ramkissoon, Lori A.; et al. (2013-05-14). "Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1". Proceedings of the National Academy of Sciences of the United States of America. 110 (20): 8188–8193. doi:10.1073/pnas.1300252110. ISSN 1091-6490. PMC 3657784. PMID 23633565.
- ↑ Bale, Tejus A.; et al. (2022-07). "The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low-grade gliomas and glioneuronal tumors". Brain Pathology (Zurich, Switzerland). 32 (4): e13060. doi:10.1111/bpa.13060. ISSN 1750-3639. PMC 9245930 Check
|pmc=
value (help). PMID 35218102 Check|pmid=
value (help). Check date values in:|date=
(help)
Notes
*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.